Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
Marín-Aguilera M, Jares P, Sanfeliu E, Villacampa G, Hernández-Lllán E, Martínez-Puchol AI, Shankar S, González-Farré B, Waks AG, Brasó-Maristany F, Pardo F, Manning DK, Abery JA, Curaba J, Moon L, Gordon O, Galván P, Wachirakantapong P, Castillo O, Nee CM, Blasco P, Senevirathne TH, Sirenko V, Martínez-Sáez O, Aguirre A, Krop IE, Li Z, Spellman P, Metzger Filho O, Polyak K, Michaels P, Puig-Butillé JA, Vivancos A, Matito J, Buckingham W, Perou CM, Villagrasa-González P, Prat A, Parker JS, Paré L. Marín-Aguilera M, et al. Among authors: sanfeliu e. ESMO Open. 2024 Mar;9(3):102903. doi: 10.1016/j.esmoop.2024.102903. Epub 2024 Mar 6. ESMO Open. 2024. PMID: 38452436 Free PMC article.
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
Prat A, Guarneri V, Pascual T, Brasó-Maristany F, Sanfeliu E, Paré L, Schettini F, Martínez D, Jares P, Griguolo G, Dieci MV, Cortés J, Llombart-Cussac A, Conte B, Marín-Aguilera M, Chic N, Puig-Butillé JA, Martínez A, Galván P, Tsai YH, González-Farré B, Mira A, Vivancos A, Villagrasa P, Parker JS, Conte P, Perou CM. Prat A, et al. Among authors: sanfeliu e. EBioMedicine. 2022 Jan;75:103801. doi: 10.1016/j.ebiom.2021.103801. Epub 2022 Jan 3. EBioMedicine. 2022. PMID: 34990895 Free PMC article.
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Brasó-Maristany F, Griguolo G, Chic N, Pascual T, Paré L, Maues J, Galván P, Dieci MV, Miglietta F, Giarratano T, Martínez-Sáez O, Marín-Aguilera M, Schettini F, Conte B, Angelats L, Vidal M, Adamo B, Muñoz M, Sanfeliu E, González B, Vivancos A, Villagrasa P, Parker JS, Perou CM, Conte P, Prat A, Guarneri V. Brasó-Maristany F, et al. Among authors: sanfeliu e. J Natl Cancer Inst. 2023 Mar 9;115(3):332-336. doi: 10.1093/jnci/djac227. J Natl Cancer Inst. 2023. PMID: 36576009 Free PMC article.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A, Guarneri V, Paré L, Griguolo G, Pascual T, Dieci MV, Chic N, González-Farré B, Frassoldati A, Sanfeliu E, Cejalvo JM, Muñoz M, Bisagni G, Brasó-Maristany F, Urso L, Vidal M, Brandes AA, Adamo B, Musolino A, Miglietta F, Conte B, Oliveira M, Saura C, Pernas S, Alarcón J, Llombart-Cussac A, Cortés J, Manso L, López R, Ciruelos E, Schettini F, Villagrasa P, Carey LA, Perou CM, Piacentini F, D'Amico R, Tagliafico E, Parker JS, Conte P. Prat A, et al. Among authors: sanfeliu e. Lancet Oncol. 2020 Nov;21(11):1455-1464. doi: 10.1016/S1470-2045(20)30450-2. Lancet Oncol. 2020. PMID: 33152285 Free PMC article. Clinical Trial.
Gene expression profiles of breast cancer metastasis according to organ site.
Brasó-Maristany F, Paré L, Chic N, Martínez-Sáez O, Pascual T, Mallafré-Larrosa M, Schettini F, González-Farré B, Sanfeliu E, Martínez D, Galván P, Barnadas E, Salinas B, Tolosa P, Ciruelos E, Carcelero E, Guillén C, Adamo B, Moreno R, Vidal M, Muñoz M, Prat A. Brasó-Maristany F, et al. Among authors: sanfeliu e. Mol Oncol. 2022 Jan;16(1):69-87. doi: 10.1002/1878-0261.13021. Epub 2021 Jun 23. Mol Oncol. 2022. PMID: 34051058 Free PMC article.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
Chic N, Schettini F, Brasó-Maristany F, Sanfeliu E, Adamo B, Vidal M, Martínez D, Galván P, González-Farré B, Cortés J, Gavilá J, Saura C, Oliveira M, Pernas S, Martínez-Sáez O, Soberino J, Ciruelos E, Carey LA, Muñoz M, Perou CM, Pascual T, Bellet M, Prat A. Chic N, et al. Among authors: sanfeliu e. EBioMedicine. 2021 Jul;69:103451. doi: 10.1016/j.ebiom.2021.103451. Epub 2021 Jun 20. EBioMedicine. 2021. PMID: 34161883 Free PMC article. Clinical Trial.
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.
Brasó-Maristany F, Sansó M, Chic N, Martínez D, González-Farré B, Sanfeliu E, Ghiglione L, Carcelero E, Garcia-Corbacho J, Sánchez M, Soy D, Jares P, Peg V, Saura C, Muñoz M, Prat A, Vivancos A. Brasó-Maristany F, et al. Among authors: sanfeliu e. Front Oncol. 2021 Sep 20;11:710596. doi: 10.3389/fonc.2021.710596. eCollection 2021. Front Oncol. 2021. PMID: 34616675 Free PMC article.
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report.
Schettini F, Seguí E, Conte B, Sanfeliu E, Gonzalez-Farre B, Jares P, Vidal-Sicart S, Ganau S, Cebrecos I, Brasó-Maristany F, Muñoz M, Prat A, Vidal M. Schettini F, et al. Among authors: sanfeliu e. Front Oncol. 2022 Nov 8;12:1009352. doi: 10.3389/fonc.2022.1009352. eCollection 2022. Front Oncol. 2022. PMID: 36425558 Free PMC article.
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.
Prat A, Brasó-Maristany F, Martínez-Sáez O, Sanfeliu E, Xia Y, Bellet M, Galván P, Martínez D, Pascual T, Marín-Aguilera M, Rodríguez A, Chic N, Adamo B, Paré L, Vidal M, Margelí M, Ballana E, Gómez-Rey M, Oliveira M, Felip E, Matito J, Sánchez-Bayona R, Suñol A, Saura C, Ciruelos E, Tolosa P, Muñoz M, González-Farré B, Villagrasa P, Parker JS, Perou CM, Vivancos A. Prat A, et al. Among authors: sanfeliu e. Nat Commun. 2023 Mar 1;14(1):1157. doi: 10.1038/s41467-023-36801-9. Nat Commun. 2023. PMID: 36859416 Free PMC article.
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
Oliveira M, Falato C, Cejalvo JM, Vila MM, Tolosa P, Salvador-Bofill FJ, Cruz J, Arumi M, Luna AM, Guerra JA, Vidal M, Martínez-Sáez O, Paré L, González-Farré B, Sanfeliu E, Ciruelos E, Espinosa-Bravo M, Pernas S, Izarzugaza Y, Esker S, Fan PD, Parul P, Santhanagopal A, Sellami D, Villacampa G, Ferrero-Cafiero JM, Pascual T, Prat A. Oliveira M, et al. Among authors: sanfeliu e. Ann Oncol. 2023 Aug;34(8):670-680. doi: 10.1016/j.annonc.2023.05.004. Epub 2023 May 19. Ann Oncol. 2023. PMID: 37211044 Free article.
42 results